Crescent Biopharma said it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year. It plans to start the first of multiple Phase III studies in early 2028.
CBIO · Crescent Biopharma, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 60%
- Last earnings
- May 26, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Crescent Biopharma said three of its programs are now dosing patients in the clinic, and it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year, and plans to start the first of multiple Phase III studies by early 2028.
Crescent Biopharma completed Phase 1/2 ASCEND dose escalation after dosing more than 125 patients and plans initial CR-001 monotherapy data in Q1 2027. Cash was $289.4 million as of September 30, 2026, funding operations into the second half of 2028.
Crescent Biopharma, Inc. initiated the global Phase 1/2 APOLLO trial in the fourth quarter of 2026 and reported a nine-month net loss of $85.8 million. Cash was $289.4 million as of September 30, 2026.
Crescent Bio plans Q1-2027 safety and tolerability data from 125-plus CR001 monotherapy patients, plus ORR results for up to 12 frontline non-small cell lung cancer patients against a 50 percent benchmark.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| IND clearances achieved by partnership | 9 | this year | — |
| Ordinary shares and ordinary share equivalents outstanding | 44.1M | As of September 30, 2026 | — |
| Patients dosed in ASCEND trial | 125 | as of the release date (more than 125 patients dosed) | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBIO
this stock
Crescent Biopharma, Inc.
|
$505.64M | +9.6% | -99.9% | — | 10.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 26
Crescent Biopharma said three of its programs are now dosing patients in the clinic, and it has cleared nine INDs with partner Colune Biotech this year. It expects over 2,000 patients dosed across its portfolio by the middle of next year, and plans to start the first of multiple Phase III studies by early 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBIO | -8.1% | +1.4% | -23.6% | -3.6% | +9.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +0.4% | +10.6% | -14.4% | +5.2% | +8.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.